CDN STBBI Guidelines vs Probiotic Guide Canada

Note: This application is intended for use by HEALTH PROFESSIONALS, and not the general public. For general information on sexually transmitted infections (STIs), refer to https://www.canada.ca/en/public-health/services/diseases.html This application provides Canadian health professionals with up-to-date recommendations for the screening, diagnosis, management, and treatment of STIs, including recommendations for antibiotic-resistant gonorrhea, in a convenient, concise, and easy to use format.
 It has been developed from the 2010 version of the Canadian Guidelines on Sexually Transmitted Infections (Guidelines) (http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php) and revised content from 2013 to 2016. These updates reflect emerging issues/trends affecting the management of STIs in Canada. Up-to-date information from other complementary resources has also been incorporated, including key recommendations from the HIV Screening and Testing Guide (2012) and the Management of Hepatitis B - Quick Reference (2013).
 The content is reflective of the most current evidence for the management of uncomplicated STIs in adults and youth only. It does not contain information for the management of STIs in pregnant women, children, neonates or complicated infections. 
 This application is intended to provide information to public health and clinical professionals and does not supersede any provincial/territorial legislative, regulatory, policy and practice requirements or professional guidelines that govern the practice of health professionals in their respective jurisdictions, whose recommendations may differ due to local epidemiology or context.

WHAT is this: A Practice Tool to Assist with Clinical Decision Making for Appropriate Probiotic Therapy for Your Patients WHO is the intended user: This Clinical Guide is designed to translate scientific evidence available for probiotic products to practical, clinically relevant information. It is intended to be used as clinical decision-making tool, enabling clinicians to easily select the appropriate product, dose, and formulation for a specific indication. WHY is this needed: Currently, the body of evidence for probiotic interventions is growing along with popular demand for these products. There is evidence to support the use of probiotic products for a variety of indications beyond gut health, however applications and results are strain-specific. Due to frequent changes in commercial availability of probiotic strains, new published evidence and growing research, an annual review and updates of this Clinical Guide have been conducted since 2008. A general lack of adverse effects attributable to probiotics supports the wide use of these products, but ongoing investigation is recommended.